Given the worldwide demand for vaccines to stop the spread of COVID-19, experts believe it will be important to move as many promising candidates forward as possible.
Department of Medicine
Nigwekar Lab: Sagar Nigwekar, MD, MMSc
Explore This Research Lab
My primary research focus is calciphylaxis (also known as calcific uremic arteriolopathy) and it aims to develop effective treatments and diagnostic tests for patients with calciphylaxis.Calciphylaxis, a dermal arteriolar calcification disorder, has significant mortality and morbidity. I am leading multiple research studies in calciphylaxis patients. These studies address risk factors and pathogenesis of calciphylaxis and guide development and examination of novel treatments and diagnostic modalities for this highly fatal disease. Our team is currently enrolling patients in the first ever randomized controlled trial for calciphylaxis wherein we are testing vitamin K supplementation as a potential therapy. More details regarding this trial are available at Clinicaltrials.gov.
Our team also aims to apply the knowledge gained from calciphylaxis research to investigate other forms of vascular calcifications.
I am also involved in the epidemiological and translational investigations in the areas of hyponatremia, nephrolithiasis, and olfaction-malnutrition.
- Nigwekar SU. An unusual case of nonhealing leg ulcer in a diabetic patient.South Med J. 2007; 100(8):851-2. PMID: 17713318.
- Nigwekar SU, Wolf M, Sterns RH, Hix JK. Calciphylaxis from nonuremic causes: a systematic review. Clin J Am Soc Nephrol. 2008; 3(4):1139-43. PMID: 18417747; PMCID: PMC2440281
- Nigwekar SU, Brunelli SM, Meade D, Wang W, Hymes J, Lacson E Jr. Sodium thiosulfate therapy for calcific uremic arteriolopathy. Clin J Am Soc Nephrol. 2013; 8(7):1162-70. PMID: 23520041; PMCID: PMC3700696.
- Nigwekar SU, Bhan I, Turchin A, Skentzos SC, Hajhosseiny R, Steele D, Nazarian RM, Wenger J, Parikh S, Karumanchi A, Thadhani R. Statin use and calcific uremic arteriolopathy: a matched case-control study. Am J Nephrol. 2013; 37(4):325-32. PMID: 23548843; PMCID: PMC4110510.
- Nigwekar SU, Wenger J, Thadhani R, Bhan I. Hyponatremia, mineral metabolism, and mortality in incident maintenance hemodialysis patients: a cohort study. Am J Kidney Dis. 2013; 62(4):755-62. PMID: 23591291; PMCID: PMC3972035.
- Strazzula L, Nigwekar SU, Steele D, Tsiaras W, Sise M, Bis S, Smith GP, Kroshinsky D. Intralesional sodium thiosulfate for the treatment of calciphylaxis. JAMA Dermatol. 2013; 149(8):946-9. PMID: 23760631
- Allegretti AS, Nazarian RM, Goverman J, Nigwekar SU. Calciphylaxis: a rare but fatal delayed complication of Roux-en-Y gastric bypass surgery. Am J Kidney Dis. 2014;64(2):274-7. PMID: 24787764.
- Nigwekar SU, Solid CA, Ankers E, Malhotra R, Eggert W, Turchin A, Thadhani RI, Herzog CA. Quantifying a rare disease in administrative data: the example of calciphylaxis. J Gen Intern Med. 2014;29 Suppl 3:S724-31. PMID: 25029979; PMCID: PMC4124115.
- Nigwekar SU, Kroshinsky D, Nazarian RM, Goverman J, Malhotra R, Jackson VA, Kamdar MM, Steele DJ, Thadhani RI. Calciphylaxis: risk factors, diagnosis, and treatment. Am J Kidney Dis. 2015; 66(1):133-46. PMID: 25960299; PMCID: PMC4696752.
- Lloyd WR, Agarwal S, Nigwekar SU, Esmonde-White K, Loder S, Fagan S, Goverman J, Olsen BR, Jumlongras D, Morris MD, Levi B. Raman spectroscopy for label-free identification of calciphylaxis. J Biomed Opt. 2015; 20(8):80501. PMID: 26263412; PMCID: PMC4689104.
- Nigwekar SU. Multidisciplinary approach to calcific uremic arteriolopathy.Curr Opin Nephrol Hypertens. 2015; 24(6):531-7. PMID: 26371529.
- Paul S, Rabito CA, Vedak P, Nigwekar SU, Kroshinsky D. The Role of Bone Scintigraphy in the Diagnosis of Calciphylaxis. JAMA Dermatol. 2015 Dec 16. [Epub ahead of print] PMID: 26677101.
- Department of Medicine
- Press Release
- Jun | 9 | 2020
A drug already in use for several cancers was found effective in a study of leptomeningeal dissemination of cancer.
- Press Release
- Jun | 2 | 2020
A team led by investigators at Mass General and the Broad Institute of MIT and Harvard recently found that applying “polygenic risk scores” can identify at-risk patients who are not presently identified through standard clinical evaluations.
- Press Release
- May | 15 | 2020
A team led by researchers from Mass General has uncovered key molecular step stones in alcohol-related liver disease that may provide targets for drug therapy development.
- May | 12 | 2020
Neutralizando los anticuerpos específicos del SARS-CoV-2 y las células T específicas del virus detectadas en personas que se recuperan del COVID-19
El más reciente estudio sobre la inmunidad protectora en pacientes que se recuperan del COVID-19, publicado en Immunity, es el más completo hasta ahora. Sus prometedores resultados son discutidos por Tiara Calhoun, MD, y Vladimir Vinarsky, MD, con la asesoría de Rod Rahimi, MD, PhD.
- May | 1 | 2020
The National Institute of Allergy and Infectious Diseases (NIAID) reported April 29 that preliminary data from the study indicates that patients with advanced COVID-19 symptoms who received remdesivir recovered 31% faster than similar patients who received a placebo.
About the Nephrology Division
The Division of Nephrology at Massachusetts General Hospital is a leading provider of services for patients with kidney disease, including diagnosis and management of kidney diseases and medical management of renal transplantation.